Epidemiology of hepatitis E virus in Iran.
Iran is known as an endemic country for hepatitis E virus (HEV) infection, while there are variations in the epidemiology of HEV infection throughout the country. The available epidemiological studies in different regions of Iran show HEV seroprevalence of 1.1%-14.2% among general population, 4.5% -14.3% among blood donors, 6.1%-22.8% among injecting drug users, 6.3%-28.3% among hemodialysis patients, 1.6%-11.3% among patients infected with other hepatitis viruses, 27.5% among patients with chronic liver disease, 30.8% among kidney transplant recipient patients, and 10%-16.4% among human immunodeficiency virus-infected patients. These variations reflect differences in the status of public health and hygiene, risk factors, and routes of transmission in different regions and groups. Therefore, it is necessary to review the epidemiology of HEV infection to determine the most prevalent risk factors and routes of transmission, and to evaluate the effectiveness of preventive strategies employed in the public health services of the country. Moreover, the other epidemiological aspects of HEV, including the genotypic pattern, extra hepatic manifestations, and incidence of chronic infection need to be investigated among Iranian population to expand the current knowledge on the epidemiology of HEV and to clarify the real burden of HEV infection. Therefore, this review was performed to provide a general overview regarding the epidemiology of HEV in Iran.
Reza Taherkhani, Fatemeh Farshadpour, Department of Microbiology and Parasitology, School of Medicine, Bushehr University of Medical Sciences, Bushehr 7514633341, Iran.
Reza
R
Taherkhani
Reza Taherkhani, Fatemeh Farshadpour, Department of Microbiology and Parasitology, School of Medicine, Bushehr University of Medical Sciences, Bushehr 7514633341, Iran.
Fatemeh
F
Farshadpour
D060085:Coinfection; D055030:Drug Users; D016751:Hepatitis E / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy / Q000635:transmission; D016752:Hepatitis E virus / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D016867:Immunocompromised Host; D007492:Iran / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D015819:Substance Abuse, Intravenous / Q000453:epidemiology
Blood donors; Chronic liver disease; Epidemiology; General population; Hemodialysis; Hepatitis E virus; Immunocompromised patients; Injecting drug users; Iran; Prevalence